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each). Participants ate a matched standardised 40g carbohydrate
evening meal on two occasions (one without a bolus and one with
a late bolus administered 20-min post-meal commencement)
each during the FiAsp and insulin aspart stages of the study.
CGM data 0–4 hours post-meal was analysed by signed rank test.
Results: To date, nine and eight participants respectively have
completed the missed and late meal bolus challenges. While not
statistically significant, there was a higher time in target range
with FiAsp with missed bolus and a higher time in hypogly-
caemia range with late bolus (Table). There were no major hy-
poglycaemia or hyperglycaemic excursions.
Conclusions: Trends observed with a missed meal bolus
suggest that FiAsp may offer advantages over insulin aspart with
regard to full CL function though late meal-time bolus delivery
remains a risk for hypoglycaemia.
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1University Hospital Complex of Santiago de Compostela,
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Background and Aims: Fast-acting insulin aspart (fAsp) is a
faster-acting insulin with a more rapid rate of absorption and
greater early-glucose-lowering effect than conventional insulin
(iAsp). The aim of this study was to assess the postprandial
glycemic control in patients with sensor-augmented pump ther-
apy after one month of treatment with fAsp.
Methods: Five patients (2males) treated with sensor-aug-
mented pump therapy (at least 6 months prior to the initiation
of fAsp) whose age were 41 – 11 years and basal HbA1c 7,1 –
0,4%, were included. Episodes of postprandial hyperglycemia
(>140 mg/dL) were analysed before and after one-month treat-
ment with fAsp. Other variables analysed were the area under the
curve (AUC) >140 mg/dL, AUC <70 mg/dL, mean glucose and
standard deviation (mg/dL), total insulin dose (IU/day) and
basal/bolus distribution (%).
Results: Postprandial hyperglycemia episodes (>140 mg/dL)
were reduced by 9.1% after one month of treatment with fAsp.
The continuous glucose monitoring results are shown in the
following table:
Conclusions: After one-month follow-up with fAsp, hyper-
glycemia events decreased without increasing the time in hy-
poglycemia and without changes in the basal/bolus distribution,
in patients with sensor-augmented pump therapy.
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Background and Aims: Hypoglycaemia, especially nocturnal,
remains the main limiting factor of achieving good glycaemic
control in type 1 diabetes. This study aimed to investigate whether
insulin degludec in comparison with insulin glargine U100 is su-
perior in limiting the occurence of nocturnal hypoglycaemia in
patients prone to nocturnal severe hypoglycaemia.
Methods: Danish investigator-initiated, prospective, rando-
mised, open, blinded endpoint (PROBE), multicentre, cross-
over study. Adult patients with type 1 diabetes and at least one
episode of nocturnal severe hypoglycaemia during the pre-
ceding two years were included. A 1-year plus 1-year treatment
period was specified, consisting of two 3-month run-in period,
each followed by a 9-month maintenance period. The primary
endpoint was number of nocturnal symptomatic hypoglycaemic
episodes during the maintenance period, analysed by intention-
to-treat.
Results: A total of 149 patients were randomised to insulin
degludec or insulin glargine U100. When defining night-time
from 00:00 to 05:59 treatment with insulin degludec resulted in
a 28% (95%CI:5-45; p = 0.02) and 37% (95%CI:16–53; p =
0.002) relative risk reduction (RRR) of nocturnal symptomatic
hypoglycaemia £3.9 mmol/L and £3.0 mmol/L, respectively,
compared to insulin glargine U100. Similar results with insulin
degludec was demonstrated when defining night-time from
23:00 to 06:59 with a 27% (95%CI: 8–43; p = 0.01) and 34%
(95%CI:18–48; p < 0.001) RRR of nocturnal symptomatic hy-
poglycaemia £3.9 mmol/L and £3.0 mmol/L, respectively. No
significant differences in glycaemic control between treat-
ments.
Conclusions: Type 1 diabetes patients prone to nocturnal
severe hypoglycaemia had lower rates of nocturnal hypogly-
caemia with insulin degludec as compared to with insulin glar-
gine U100. The difference was relatively greater with increased
severity of nocturnal hypoglycaemia.
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Background and Aims: We investigated glycaemic vari-
ability from one day before to 6 days after switching in patients
treated with long-acting insulin.
Methods: This study was conducted during hospitalization.
20 type 2 diabetic patients on basal insulin therapy were ran-
domly allocated to two groups. In Group1, fasting blood glu-
cose level was stabilized (not exceeding 180 mg/dL) using
insulin glargine 300 U/mL (Glargine300); Glargine300 was
continued for 6 days with the same dose; a continuous glucose
monitoring device (FreeStyle Libre Pro) was worn on the fifth
day of Glargine300 administration of the same dose ( = at-
taching day:Day1); next, Glargine300 was switched to insulin
degludec (Degludec) on Day3 with the same dose, and then
Degludec was continued for 6 days with the same dose; De-
gludec was then switched to Glargine300 on Day9 with the
same dose, and then Glargine300 was continued for 6 days with
the same dose. Long-acting insulin was injected at 08:00. Test
meals were given. In Group2, patients were administered in the
order of Degludec, Glargine300, and Degludec, following the
same regimen as Group1. Evaluation duration was from 24-h
before to 144-h after switching.
Results: Mean of daily difference (MODD) between day2 and
day3 (switch day: day1) was significantly lower in patients who
switched from Glargine300 to Degludec (pGtoD) than in patients
who switched from Degludec to Glargine300 (pDtoG). The
others endpoints weren’t significantly different between pGtoD
and pDtoG (table).
Conclusions: Day-to-day glycaemic variability between day2
and day3 was lower in pGtoD than in pDtoG.
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Background and Aims: Clinical trials in free-living condi-
tions is key in the development of an Artificial Pancreas (AP)
for T1D subjects. Since the scenario plays a key role in the
synthesis and validation of AP control algorithms, a probabi-
listic approach is proposed to automatically design meal sce-
narios. In particular, we exploit our real-life data to design
realistic in silico scenarios.
Methods: The amount and time-of-day of ingested carbohy-
drates in a 1-month in 13 patients for a total of 1500 meals. have
been considered. The joint distribution of these variables has
been estimated via a copula function, in order to model their
dependence. The use of a copula allows to generate Monte Carlo
scenarios by drawing random samples, which represent a pair of
amount and time-of-day.
Results: A Gaussian copula resulted suitable for the description
of the dependence in the meal dataset with a p-value of 0.005
according to the v2 test based on Rosenblatt’s transformation.
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